SynthesisBMJ open2023
Social prescribing for children and young people with neurodisability and their families initiated in a hospital setting: a systematic review.
Synthesis in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Potential harms of social prescribing: a global umbrella review and dark logic model.BMJ open · 2026Pooled it
- Supporting Children With a Chronic Disease and Their Parents When Admitted to Hospital: A Scoping Review of Psychosocial Supports.Acta paediatrica (Oslo, Norway : 1992) · 2026Article
- EPIC-ND: a multi-site, randomised controlled trial evaluating the effectiveness of social prescribing for the unmet social needs of children with a neurodisability and their parent/carers - a study protocol.BMJ paediatrics open · 2026Article
- Identifying the active ingredients and contextual factors of social prescribing when used to support the mental health of children and young people: a qualitative study.European child & adolescent psychiatry · 2025Article
- Development of a new social prescribing intervention for families of children with cerebral palsy.Developmental medicine and child neurology · 2025Article
- Hospital in-reach family-centred social prescribing pilot for children with neurodisability: mixed methods evaluation with social return on investment analysis.BMC health services research · 2025Article
- Quality Improvement Intervention Using Social Prescribing at Discharge in a University Hospital in France: Quasi-Experimental Study.JMIR formative research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSocial prescribing (SP) is a non-medical intervention in which professionals refer patients to a link worker (LW), who connects them with appropriate support. Children and young people (CYP) with neurodisability often have unmet needs and may bypass community initiatives. We undertook a review of hospital-initiated SP for CYP with neurodisability.
designSystematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidance and using Mixed Methods Appraisal Tool. DATA SOURCES: Medline, PsycINFO, PsycARTICLES, Embase, CINAHL, Scopus, Web of Science and FutureNHS, searched from 1 January 2000 to 19 October 2023, with no language restrictions. ELIGIBILITY CRITERIA: Studies describing SP interventions for CYP (ages 0-25 years) with neurodisability/neurodivergence. EXCLUSIONS: interventions outside of secondary care; with no description; or no LW. DATA EXTRACTION AND SYNTHESIS: Two researchers independently screened references. Data were charted, summarised, quality assessments performed and narratively reviewed.
resultsAfter removal of duplicates, 518 references were identified. Following screening, eight articles (covering five SP schemes) were included. Rahi
conclusionLiterature describing hospital-initiated SP schemes for CYP with neurodisability, while sparse, suggests potential benefit. PROSPERO REGISTRATION NUMBER: CRD42022384188.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.